Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00492050 · ClinicalTrials.gov registry record · Phase 2

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

A Phase 2 study of Waldenstrom's Macroglobulinemia, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
46
Enrollment target
1
Study location

NCT00492050 is a Phase 2 study of Waldenstrom's Macroglobulinemia that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants, below the 154-participant average among 5 other Waldenstrom's Macroglobulinemia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00492050, a Phase 2 study of Waldenstrom's Macroglobulinemia, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM. This drug combination will allow researchers to collect your stem cells in case it is possible to transplant the stem cells as treatment if your WM gets worse. Researchers will also look at the safety and tolerability of this drug combination followed by treatment with other drug combinations.

Conditions Studied

Waldenstrom's Macroglobulinemia

Interventions

  • DRUG Rituximab
  • DRUG Valacyclovir
  • DRUG Bortezomib

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2006-08-02
Est. Completion 2026-06-28
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00492050

The ClinicalTrials.gov registry entry for NCT00492050 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 5 other Waldenstrom's Macroglobulinemia trials with a reported enrollment target (70% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Waldenstrom's Macroglobulinemia appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.

NCT00492050 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00492050 about?

NCT00492050 is a clinical study titled "Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia". The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM. This drug combination will allow researchers to collect your stem cells in case it is possible to transplant the stem cells as treatment if your WM gets worse. Researchers...

What is the current status of trial NCT00492050?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2006-08-02. Estimated completion is 2026-06-28.

What conditions does trial NCT00492050 study?

This clinical trial studies the following conditions: Waldenstrom's Macroglobulinemia.

What interventions are being tested in trial NCT00492050?

The interventions under investigation include: Rituximab (DRUG), Valacyclovir (DRUG), Bortezomib (DRUG).

Who is sponsoring clinical trial NCT00492050?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00492050 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Waldenstrom's Macroglobulinemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Waldenstrom's Macroglobulinemia

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.